公开(公告)号：US09585613B2

公开(公告)日：2017-03-07

申请号：US13203397

申请日：2010-02-26

申请人： Paul Cales ,  Jérôme Boursier

发明人： Paul Cales ,  Jérôme Boursier

IPC分类号： A61B5/00 ,  G06F19/00 ,  A61B8/08

CPC分类号： A61B5/416 ,  A61B5/4244 ,  A61B8/08 ,  A61B8/485 ,  G06F19/00 ,  G16H50/20

摘要： This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function. This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.

摘要翻译： 本发明涉及诊断肝脏病理学的存在和/或严重性和/或监测针对个体肝脏病理学的治疗性治疗的有效性的方法，导致包括至少一种血液 测试和从诊断肝纤维化的物理方法发出的至少一个数据，所述数据选自医学成像数据和临床测量，所述组合通过数学函数进行。 本发明还涉及一种方法，其中通过至少一次血液检查和从诊断肝纤维化的物理方法发出的至少一种数据的数学函数的组合进行至少两次，并且所述至少两个得出的分数是 在基于诊断可靠间隔的算法中组合。

公开(公告)号：US08489335B2

公开(公告)日：2013-07-16

申请号：US11596486

申请日：2005-05-13

申请人： Paul Cales

发明人： Paul Cales

IPC分类号： G01N33/48

CPC分类号： G01N33/576 ,  G01N33/6893 ,  G01N2800/085 ,  G01N2800/52 ,  G06F19/00 ,  G16H50/20 ,  Y02A90/24 ,  Y02A90/26

摘要： The invention relates to a method of diagnosing the presence and/or severity of a hepatic pathology and/or of monitoring the effectiveness of a curative treatment against a hepatic pathology in an individual, comprising the establishment of at least one non-invasive diagnostic score, in particular a diagnostic score for portal and septal fibrosis and/or an estimate score for the fibrosis area and/or an estimate score for the fractal dimension.

摘要翻译： 本发明涉及一种诊断肝病理学的存在和/或严重性和/或监测针对个体肝病理疗治疗的有效性的方法，包括建立至少一种非侵入性诊断评分， 特别是门静脉和间隔纤维化的诊断分数和/或纤维化区域的估计分数和/或分形维数的估计得分。

公开(公告)号：US20110313276A1

公开(公告)日：2011-12-22

申请号：US13129999

申请日：2009-11-18

申请人： Paul Cales ,  Christophe Aube ,  Vincent Roullier

发明人： Paul Cales ,  Christophe Aube ,  Vincent Roullier

IPC分类号： A61B5/055 ,  C12Q1/52 ,  G01N33/68 ,  G01N33/98 ,  C12Q1/02 ,  G01N33/72 ,  G01N33/92 ,  G01N33/66 ,  C12Q1/56

CPC分类号： G01N33/6893 ,  G01N2800/085 ,  G01N2800/60 ,  G16H50/30 ,  Y10T436/143333 ,  Y10T436/144444

摘要： An in-vitro non-invasive method for quantifying the lesions of the liver of the patient with metabolic steatosis addressing a diagnostic target, i.e. fibrosis, steatosis and/or steato-hepatitis (NASH) and measuring at least one marker selected from the group consisting of biomarkers and possibly clinical markers and possibly scores, the biomarkers being selected from the group consisting of glycemia, AST (aspartate aminotransferase), ALT (alanine aminotransferase), AST/ALT, AST.ALT, ferritin, platelets, prothrombin index, hyaluronic acid, haemoglobin, triglycerides; the biomarker selected from weight, body mass index, sex and age, hip perimeter, abdominal perimeter and ratio thereof; the scores being selected from score of fibrosis, area of fibrosis, fractal dimension of fibrosis, score of steatosis, area of steatosis, fractal dimension of steatosis and combining the measures in a mathematical function combining the measures through a binary (or ordinal) logistic function or multiple linear regression including the markers in order to obtain an end value.

摘要翻译： 一种体外非侵入性方法，用于量化患有代谢脂肪变性的患者的肝脏损伤，所述代谢脂肪变性涉及诊断靶标，即纤维化，脂肪变性和/或脂肪性肝炎（NASH），并测量至少一种选自以下的标志物： 生物标志物和可能的临床标志物和可能的分数，生物标志物选自血糖，AST（天冬氨酸氨基转移酶），ALT（丙氨酸氨基转移酶），AST / ALT，AST.ALT，铁蛋白，血小板，凝血酶原指数，透明质酸 ，血红蛋白，甘油三酸酯; 选自体重，体重指数，性别和年龄，臀围，腹部周长及其比例的生物标志物; 评分从纤维化评分，纤维化面积，纤维化分形维数，脂肪变性评分，脂肪变性面积，脂肪变性分形维数中选出，并结合采用二进制（或顺序）对数函数的数学函数中的措施 或包括标记的多元线性回归以获得结束值。

公开(公告)号：US20140005500A1

公开(公告)日：2014-01-02

申请号：US14004608

申请日：2012-03-12

申请人： Paul Cales ,  Jerome Boursier

发明人： Paul Cales ,  Jerome Boursier

IPC分类号： A61B5/00

CPC分类号： A61B5/4244 ,  A61B5/4842

摘要： The present invention relates to a non-invasive method for assessing the presence and/or severity of a lesion in an organ of an animal, including a human, said method comprising carrying out at least one non-invasive test resulting in a value, preferably a score result, and positioning the at least one value or score result in a class of a detailed classification, such as, for example, a detailed classification based on population percentiles, or on a reliable diagnostic interval (RDI), to be crossed with another RDI. The present invention also relates to a device, preferably a meter, carrying out the non-invasive method of the invention.

摘要翻译： 本发明涉及用于评估动物（包括人）器官中的病变的存在和/或严重性的非侵入性方法，所述方法包括进行至少一种导致值的非侵入性测试 评分结果，以及将至少一个值或得分结果定位在详细分类的类别中，例如基于人口百分位数的详细分类，或在可靠的诊断间隔（RDI）上进行交叉，以与 另一个RDI。 本发明还涉及执行本发明的非侵入性方法的装置，优选地是仪表。

公开(公告)号：US20070178442A1

公开(公告)日：2007-08-02

申请号：US11673058

申请日：2007-02-09

申请人： Ursula-Henrike Wienhues-Thelen ,  Paul Cales ,  Hendrik Huedig

发明人： Ursula-Henrike Wienhues-Thelen ,  Paul Cales ,  Hendrik Huedig

IPC分类号： C12Q1/00 ,  C12Q1/37

CPC分类号： G01N33/6893 ,  G01N2333/745 ,  G01N2333/81 ,  G01N2333/8146 ,  G01N2800/085

摘要： A method for the detection of the presence and/or the severity of a liver disease in a patient comprising measuring in an isolated sample TIMP-1 (tissue inhibitor of metalloproteinase I), ferritin, at least one additional parameter selected from the group consisting of A2M (alpha-2-macroglobulin) and PI (prothrombin index) and optionally measuring at least one additional biochemical or clinical parameter and diagnosing the presence and/or severity of a liver disease based on the presence or measured levels of these parameters. The method can be used for monitoring therapeutic treatment of liver fibrosis and staging of liver fibrosis.

摘要翻译： 一种用于检测患者中肝脏疾病的存在和/或严重性的方法，其包括在分离的样品TIMP-1（金属蛋白酶I的组织抑制剂），铁蛋白中测量至少一种附加参数，所述附加参数选自： A2M（α-2-巨球蛋白）和PI（凝血酶原指数），并且任选地基于这些参数的存在或测量水平测量至少一种额外的生物化学或临床参数并诊断肝脏疾病的存在和/或严重性。 该方法可用于监测肝纤维化的治疗和肝纤维化分期。

公开(公告)号：US20120010824A1

公开(公告)日：2012-01-12

申请号：US13257456

申请日：2010-03-18

申请人： Paul Cales

发明人： Paul Cales

IPC分类号： G06F19/10

CPC分类号： G16B5/00 ,  A61K31/00 ,  A61K31/4178 ,  A61K38/21 ,  G01N33/50 ,  G01N33/57438 ,  G01N33/576 ,  G01N33/6893 ,  G01N2333/4713 ,  G01N2333/495 ,  G01N2333/78 ,  G01N2400/40 ,  G01N2800/085 ,  G01N2800/52 ,  G01N2800/60 ,  G01N2800/7052 ,  G16H50/20 ,  G16H50/30

摘要： The present invention relates to a non-invasive method for assessing liver fibrosis progression in an individual, said method comprising the steps of calculating the ratio of fibrosis level to cause duration and to a non-invasive method for assessing liver fibrosis progression in an individual, said method comprising the steps of measuring, at two different times t1 and t2, the fibrosis levels FL (t1) and FL (t2) and calculating the ratio FL (t2)−FL (t1) to (t2−t1) and to a non-invasive method for assessing if an individual is a slow, medium or fast fibroser.

摘要翻译： 本发明涉及用于评估个体肝纤维化进展的非侵入性方法，所述方法包括以下步骤：计算纤维化水平与引起持续时间的比率以及用于评估个体肝纤维化进展的非侵入性方法， 所述方法包括以下步骤：在两个不同的时间t1和t2，测量纤维化水平FL（t1）和FL（t2），并计算比率FL（t2）-FL（t1）至（t2-t1） 非侵入性方法，用于评估个体是慢性，中型还是快速纤维细胞。

公开(公告)号：US20110306849A1

公开(公告)日：2011-12-15

申请号：US13203397

申请日：2010-02-26

申请人： Paul Cales ,  Jerome Boursier

发明人： Paul Cales ,  Jerome Boursier

IPC分类号： A61B5/00 ,  A61B8/00

CPC分类号： A61B5/416 ,  A61B5/4244 ,  A61B8/08 ,  A61B8/485 ,  G06F19/00 ,  G16H50/20

摘要： This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function. This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.

摘要翻译： 本发明涉及诊断肝脏病理学的存在和/或严重性和/或监测针对个体肝脏病理学的治疗性治疗的有效性的方法，导致包括至少一种血液 测试和从诊断肝纤维化的物理方法发出的至少一个数据，所述数据选自医学成像数据和临床测量，所述组合通过数学函数进行。 本发明还涉及一种方法，其中通过至少一次血液检查和从诊断肝纤维化的物理方法发出的至少一种数据的数学函数的组合进行至少两次，并且所述至少两个得出的得分是 在基于诊断可靠间隔的算法中组合。

公开(公告)号：US20090143993A1

公开(公告)日：2009-06-04

申请号：US11596486

申请日：2005-05-13

申请人： Paul Cales

发明人： Paul Cales

IPC分类号： G06F19/00 ,  G01N33/68

CPC分类号： G01N33/576 ,  G01N33/6893 ,  G01N2800/085 ,  G01N2800/52 ,  G06F19/00 ,  G16H50/20 ,  Y02A90/24 ,  Y02A90/26

摘要： The invention relates to a method of diagnosing the presence and/or severity of a hepatic pathology and/or of monitoring the effectiveness of a curative treatment against a hepatic pathology in an individual, comprising the establishment of at least one non-invasive diagnostic score, in particular a diagnostic score for portal and septal fibrosis and/or an estimate score for the fibrosis area and/or an estimate score for the fractal dimension.

摘要翻译： 本发明涉及一种诊断肝病理学的存在和/或严重性和/或监测针对个体肝病理疗治疗的有效性的方法，包括建立至少一种非侵入性诊断评分， 特别是门静脉和间隔纤维化的诊断分数和/或纤维化区域的估计分数和/或分形维数的估计得分。

公开(公告)号：US20070178443A1

公开(公告)日：2007-08-02

申请号：US11673072

申请日：2007-02-09

申请人： Ursula-Henrike Wienhues-Thelen ,  Paul Cales ,  Hendrik Huedig

发明人： Ursula-Henrike Wienhues-Thelen ,  Paul Cales ,  Hendrik Huedig

IPC分类号： C12Q1/00 ,  C12Q1/37

CPC分类号： G01N33/6893 ,  G01N2333/745 ,  G01N2333/81 ,  G01N2333/8146 ,  G01N2800/085 ,  G01N2800/52

摘要： The invention concerns a method for the detection of the presence and/or the severity of a liver disease in a patient comprising measuring in an isolated sample TIMP-1 (Tissue Inhibitor of Metalloproteinase I), A2M (a-2-macroglobulin), PLT (number of blood plateletes, PI (prothrombin index), optionally at least one additional parameter selected from the group consisting of urea and GGT (γ-glutamyltranspeptidase) and optionally measuring at least one additional biochemical or clinical parameter and diagnosing the presence and/or severity of a liver disease based on the presence or measured levels of these parameters. The method can be used for monitoring therapeutic treatment of liver fibrosis and staging of liver fibrosis.

摘要翻译： 本发明涉及用于检测患者肝脏疾病存在和/或严重程度的方法，包括在分离的样品中测量TIMP-1（金属蛋白酶I的组织抑制剂），A2M（a-2-巨球蛋白），PLT （血小板数，PI（凝血酶原指数）），任选地至少一种选自脲和GGT（γ-谷氨酰转肽酶）的附加参数，并任选地测量至少一种额外的生物化学或临床参数，并诊断存在和/或 基于这些参数的存在或测量水平，肝脏疾病的严重程度，可用于监测肝纤维化的治疗和肝纤维化分期。